HEALTH PROFESSIONAL · SOURCE READING

Treatment Option Overview for CML

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Treatment of patients with chronic myeloid leukemia (CML) is usually initiated at diagnosis, which is based on the presence of an elevated white blood cell count, splenomegaly, thrombocytosis, and identification of the BCR::ABL1 translocation.[1]

Source links and citations

Table 1. Treatment Options for CML Phases
Phase	Treatment Options
BMT = bone marrow transplant; CML = chronic myeloid leukemia; SCT = stem cell transplant; TKIs = tyrosine kinase inhibitors.
Chronic-phase CML	Targeted therapy with an allosteric inhibitor of BCR::ABL1 at the ABL1 myristoyl pocket
	Targeted therapy with other BCR::ABL1 TKIs
	Allogeneic BMT or SCT
Accelerated-phase CML	Targeted therapy with TKIs
Accelerated-phase CML	Allogeneic SCT
Blastic-phase CML	Targeted therapy with TKIs
Blastic-phase CML	Allogeneic BMT or SCT
Relapsed CML	Targeted therapy with TKIs

Source links and citations

Continue within this section

Targeted Therapy With Tyrosine Kinase Inhibitors (TKIs) →Allogeneic Bone Marrow Transplant (BMT) or Stem Cell Transplant (SCT) →Interferon Alfa →Hydroxyurea →

Publication references

Read the original reference and check its publication notices.

PubMed 34425075 · Original source

Preserved source evidence · Not medical advice